Welcome to our dedicated page for UroGen Pharma Ltd. SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UroGen Pharma Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UroGen Pharma Ltd.'s regulatory disclosures and financial reporting.
Arie Belldegrun, a director of UroGen Pharma Ltd. (URGN), reported an equity award on 08/26/2025. The Form 4 shows acquisition of 20,000 stock options with an exercise price of $19.50. The options become exercisable on 08/26/2025 and expire on 08/26/2035, and the reporting person beneficially owns 20,000 underlying ordinary shares following the transaction. Per the filing, the shares underlying the option will vest in equal quarterly installments over one year, contingent on the directors continuous service under the 2017 Equity Incentive Plan. The Form 4 was signed via attorney-in-fact on 08/27/2025.
UroGen Pharma Ltd. reported the results of its 2025 annual shareholder meeting. Shareholders approved an Amended and Restated Non-Employee Director and Officer Compensation Policy and an amendment to the 2017 Equity Incentive Plan that, among other changes, increases the number of ordinary shares authorized for issuance under the plan by 2,750,000 shares.
All seven director nominees were elected. Shareholders gave advisory approval to the compensation of named executive officers and chose an annual schedule for future advisory votes on executive pay, which the board adopted until at least the 2031 annual meeting. Shareholders also approved the engagement of PricewaterhouseCoopers LLP as independent auditor until the 2026 annual meeting.
RA Capital Management, L.P., two individuals (Peter Kolchinsky and Rajeev Shah) and RA Capital Healthcare Fund, L.P. filed an Amendment to Schedule 13G for UroGen Pharma Ltd. (ticker URGN) reporting ordinary shares, CUSIP M96088105. The filing states that as of June 30, 2025 each Reporting Person beneficially owned 0 shares (0.0%) of UroGen and disclaims status as a group. The filing provides the Reporting Persons' principal business address in Boston and certifies the holdings were not acquired to influence control of the issuer.
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), sold 10,000 ordinary shares on 08/11/2025 at a weighted-average price of $17.69 per share. After the transaction he directly beneficially owned 148,229 shares. The filing reports the sale under Transaction Code S and notes the shares were sold in multiple trades at prices ranging from $17.63 to $17.76.
No derivative (options, warrants, or convertible) transactions are reported on this Form 4 and the reporting person indicates availability of further breakdown information on request.
Paradigm BioCapital and affiliated reporting persons disclosed passive beneficial ownership of UroGen Pharma Ltd. ordinary shares. The Adviser, the Adviser GP and Senai Asefaw each report sole beneficial ownership of 2,332,066 shares, equal to 5.0% of the outstanding class, while Paradigm BioCapital International Fund Ltd. reports 2,056,187 shares or 4.4%. These percentages are calculated using 46,264,132 ordinary shares outstanding as reported by the issuer.
The statement is filed on Schedule 13G, which the reporting persons use to indicate passive holdings; the filing includes a certification that the shares were not acquired to change or influence control and disclaims beneficial ownership beyond the shares directly held. Principal business addresses and organizational jurisdictions for each reporting person are provided.